Kirson Eilon D. 4

Accession 0001209191-18-036127

CIK 0001645113other

View on SEC.gov Company Profile

Filed

Jun 5, 8:00 PM ET

Accepted

Jun 6, 5:28 PM ET

Size

22.6 KB

Accession

0001209191-18-036127

Insider Transaction Report

Form 4

Period: 2018-06-04

NovoCure LtdNVCR

Kirson Eilon D.

Chief Science Officer

Transactions

Exercise/Conversion
Ordinary Shares
2018-06-04$7.03/sh+218,781$1,538,030→ 258,363 total
Sale
Ordinary Shares
2018-06-04$28.60/sh−225,296$6,443,466→ 33,067 total
Exercise/Conversion
Ordinary Shares
2018-06-04$7.48/sh+59,130$442,292→ 92,197 total
Exercise/Conversion
Ordinary Shares
2018-06-04$7.15/sh+68,250$487,988→ 160,447 total
Sale
Ordinary Shares
2018-06-04$30.26/sh−1,800$54,468→ 43,713 total
Sale
Ordinary Shares
2018-06-04$31.74/sh−4,131$131,118→ 39,582 total
Exercise/Conversion
Options to Buy Ordinary Shares
2018-06-04+218,781→ 0 total
Exercise: $7.03Exp: 2023-02-19→ Ordinary Shares (218,781 underlying)
Sale
Ordinary Shares
2018-06-04$29.36/sh−114,934$3,374,462→ 45,513 total
Exercise/Conversion
Options to Buy Ordinary Shares
2018-06-04+59,130→ 0 total
Exercise: $7.48Exp: 2024-02-25→ Ordinary Shares (59,130 underlying)
Exercise/Conversion
Options to Buy Ordinary Shares
2018-06-04+68,250→ 204,750 total
Exercise: $7.15Exp: 2027-02-21→ Ordinary Shares (68,250 underlying)

Footnotes (5)

[F1]On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 225,296 shares in multiple trades at prices ranging from $28.00 to $28.99. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F2]On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 114,934 shares in multiple trades at prices ranging from $29.00 to $29.99. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F3]On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 1,800 shares in multiple trades at prices ranging from $30.00 to $30.99. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F4]On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 4,131 shares in multiple trades at prices ranging from $31.00 to $31.99. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F5]Options exercised were fully vested as of the date hereof.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

NovoCure Ltd

CIK 0001645113

→

Entity typeother

Related Parties

filerCIK 0001654356

Filing Metadata

Form type: 4
Filed: Jun 5, 8:00 PM ET
Accepted: Jun 6, 5:28 PM ET
Size: 22.6 KB

View on SEC.gov